Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HGFAC | Q04756 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908805 | 0.95 | HGFAC (0.39) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908802 | 0.93 | MAPT (0.44) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908806 | 0.91 | HGFAC (0.41) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908891 | 0.88 | THRB (0.40) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908801 | 0.87 | MAPT (0.46) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908803 | 0.84 | HGFAC (0.43) | HGFACMAPTKDM4EPOLBMAPK1 | |
| SCHEMBL9908798 | 0.83 | MAPT (0.47) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL9908889 | 0.82 | THRB (0.39) | HGFACTHRBMAPTKDM4EPOLB | |
| SCHEMBL13768098 | 0.82 | MAPT (0.44) | THRBMAPTKDM4EPOLBMAPK1 | |
| SCHEMBL9906511 | 0.79 | HGFAC (0.41) | HGFACMAPTKDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8197710-B2 | Polymerizable compound and polymerizable composition | ADEKA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20100294990-A1 | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | ADEKA CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100294990-A1 | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | PYM1, SCO2, ZYX | HGFAC 3700/4885THRB 1211/4885MAPT 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.